Literature DB >> 15809669

Wnt signalling and prostate cancer.

G W Yardy1, S F Brewster.   

Abstract

The Wnt signalling pathway plays a role in the direction of embryological development and maintenance of stem cell populations. Heritable alterations in genes encoding molecules of the Wnt pathway, including mutation and epigenetic events, have been demonstrated in a variety of cancers. It has been proposed that disruption of this pathway is a significant step in the development of many tumours. Interactions between beta-catenin--the effector molecule of the Wnt pathway--and the androgen receptor highlight the pathway's relevance to urological malignancy. Mutation or altered expression of Wnt genes in tumours may give prognostic information and treatments are being developed which target this pathway.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15809669     DOI: 10.1038/sj.pcan.4500794

Source DB:  PubMed          Journal:  Prostate Cancer Prostatic Dis        ISSN: 1365-7852            Impact factor:   5.554


  68 in total

1.  Activation of β-catenin signaling in androgen receptor-negative prostate cancer cells.

Authors:  Xinhai Wan; Jie Liu; Jing-Fang Lu; Vassiliki Tzelepi; Jun Yang; Michael W Starbuck; Lixia Diao; Jing Wang; Eleni Efstathiou; Elba S Vazquez; Patricia Troncoso; Sankar N Maity; Nora M Navone
Journal:  Clin Cancer Res       Date:  2012-02-01       Impact factor: 12.531

2.  p21CIP-1/WAF-1 induction is required to inhibit prostate cancer growth elicited by deficient expression of the Wnt inhibitor Dickkopf-1.

Authors:  Christopher L Hall; Honglai Zhang; Shobun Baile; Mats Ljungman; Stuart Kuhstoss; Evan T Keller
Journal:  Cancer Res       Date:  2010-11-23       Impact factor: 12.701

Review 3.  Molecular signaling pathways that regulate prostate gland development.

Authors:  Gail S Prins; Oliver Putz
Journal:  Differentiation       Date:  2008-05-07       Impact factor: 3.880

4.  Network-based prediction for sources of transcriptional dysregulation using latent pathway identification analysis.

Authors:  Lisa Pham; Lisa Christadore; Scott Schaus; Eric D Kolaczyk
Journal:  Proc Natl Acad Sci U S A       Date:  2011-07-25       Impact factor: 11.205

5.  Lupeol inhibits proliferation of human prostate cancer cells by targeting beta-catenin signaling.

Authors:  Mohammad Saleem; Imtiyaz Murtaza; Rohinton S Tarapore; Yewseok Suh; Vaqar Mustafa Adhami; Jeremy James Johnson; Imtiaz Ahmad Siddiqui; Naghma Khan; Mohammad Asim; Bilal Bin Hafeez; Mohammed Talha Shekhani; Benyi Li; Hasan Mukhtar
Journal:  Carcinogenesis       Date:  2009-02-20       Impact factor: 4.944

6.  Activation of beta-Catenin in mouse prostate causes HGPIN and continuous prostate growth after castration.

Authors:  Xiuping Yu; Yongqing Wang; Ming Jiang; Brian Bierie; Pradip Roy-Burman; Michael M Shen; Makoto Mark Taketo; Marcia Wills; Robert J Matusik
Journal:  Prostate       Date:  2009-02-15       Impact factor: 4.104

7.  Axin2 expression identifies progenitor cells in the murine prostate.

Authors:  Christopher S Ontiveros; Sarah N Salm; E Lynette Wilson
Journal:  Prostate       Date:  2008-09-01       Impact factor: 4.104

8.  Dickkopf-1 expression increases early in prostate cancer development and decreases during progression from primary tumor to metastasis.

Authors:  Christopher L Hall; Stephanie D Daignault; Rajal B Shah; Kenneth J Pienta; Evan T Keller
Journal:  Prostate       Date:  2008-09-15       Impact factor: 4.104

9.  Role of DAB2IP in modulating epithelial-to-mesenchymal transition and prostate cancer metastasis.

Authors:  Daxing Xie; Crystal Gore; Jun Liu; Rey-Chen Pong; Ralph Mason; Guiyang Hao; Michael Long; Wareef Kabbani; Luyang Yu; Haifeng Zhang; Hong Chen; Xiankai Sun; David A Boothman; Wang Min; Jer-Tsong Hsieh
Journal:  Proc Natl Acad Sci U S A       Date:  2010-01-13       Impact factor: 11.205

10.  Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells.

Authors:  Hongjuan Zhao; Vincent Flamand; Donna M Peehl
Journal:  BMC Med Genomics       Date:  2009-08-20       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.